Topic

Articles

Cliodhna McDonough-Stevens looks at what the COVID-19 pandemic might mean for the future of cell and gene therapy across Europe.

Has COVID-19 Opened up the Route to Market for Cell and Gene Therapy?

Jenny Sherak, SVP & President of Specialty Physician Services at AmerisourceBergen, talks about how the needs of physician practices have evolved during the COVID-19 pandemic and what is required to navigate the shifting healthcare landscape.

Physician Practices Post-Pandemic: Q&A with Jenny Sherak, AmerisourceBergen

The Center for Biologics Evaluation and Research’s top priority is to approve biologics license applications (BLAs) to address vaccine hesitancy, according to CBER director Peter Marks.

Full Approval of COVID Vaccines Key to Addressing Hesitancy

Julian Upton is Pharmaceutical Executive’s European and Online Editor. He can be reached at 

How Gilead readied remdesivir for the COVID challenge.

Betting on Its Base in Virology

Inside Regeneron’s monoclonal antibody development to treat COVID.

Scientific Rigor, Urgent Action

Past lessons, strong resolve, and complex coordination propel J&J’s vaccine efforts.

Meeting the Crisis Head-On

Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mjhlifesciences.com

Thrust into a commercial-stage company in just months, Moderna moves full steam ahead.

Innovation in High Gear

College roommates, industry partnerships help bring Pfizer vaccine to fruition.

Bonds Old and New to the Rescue

Jill Wechsler is Pharm Exec's Washington Corespondent

Biden administration supports a notable increase in funding for public health and research as a lead priority for the coming year.

Biden Budget “Wish List” Maps FDA, Healthcare Priorities

Dr. Andrea Pfeifer is Chief Executive Officer and co-founder of AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases.

Dr. William Mobley is Distinguished Professor of Neurosciences at UC San Diego, where his laboratory studies the biology of Down syndrome, in particular the emergence of Alzheimer disease. He served as a site principal investigator in the recently completed AC Immune-sponsored vaccination trial in people with Down syndrome.

It's time to apply the same COVID-19 urgency to other devastating diseases, such as Alzheimer’s, write Andrea Pfeifer and William Mobley.